Sanofi buys US biopharma group Blueprint in $9.1 bln deal

Blueprint Medicines

02/06/2025 06:18

PARIS, June 2 (Reuters) - French pharma group Sanofi SASY.PA has agreed to buy US-based Blueprint Medicines Corporation BPMC.O, a biopharmaceutical company specializing in systemic mastocytosis, a rare immunological disease, the companies said on Monday.

Under the terms of the acquisition, Sanofi will pay $129.00 per share in cash, representing an equity value of approximately $9.1 billion.

 (Reporting by GV De Clercq;
Editing by Sudip Kar-Gupta)

 ((geert.declercq@tr.com;))